industry

Our drug Ranitidine is safe: Strides Pharma


Amid a raging controversy over commonly used heartburn drug Ranitidine, Strides pharma science today said that its drug is safe. The company said that the test results provided by the US Food and Drug Authority (FDA) found that Strides’ Ranitidine tablets 300 mg was within the “acceptable limits” for the presence of a probable cancer causing substance.

The company is likely to resume drug sale, following the report. “The Company intends to provide additional updates in the next coming days, including potential recommencement,” it said in a statement.

The Bengaluru-based company had last month suspended the manufacturing and sale of the drug following concerns around the cancer-causing impurity called N-nitrosodimethylanine (NDMA).

Citing a FDA test report, the company on Monday said that “The agency tested numerous Ranitidine products on the market over the past few months and released a summary of the results they have to date. In the summary of test results provided by USFDA, Strides’ Ranitidine Tablets 300 mg (Rx) is within the acceptable limits for NDMA of 96 nanograms per day or 0.32 ppm,” it added.

Earlier in September, the US and European Union regulators had said that they were investigating the discovery of carcinogen NDMA, in branded and generic Zantac. However, this Friday, the U.S. drug regulator downplayed the risk caused by contamination and said its tests suggest it does not cause carcinogens.

Janet Woodcock, director of the FDA’s Center for Drug Evaluation and Research, said in a statement that the levels of the probable carcinogen N-nitrosodimethylamine (NDMA) it found in Ranitidine – sold under the brand name Zantac – “are similar to the levels you would expect to be exposed to if you ate common foods like grilled or smoked meats.”

Ranitidine is a commonly prescribed medicine for countering acidity and is on the World Health Organisation’s Model List of Essential Medicines. In India, a host of companies including GalxoSmithKline, JB Chemicals, Cadila Pharma, Zydus Cadila, Dr Reddy’s and Sun Pharmaceuticals sell over 180 versions of the drug.

The market size for Ranitidine brand in India is Rs 688.6 crore, as per data shared by AIOCD PharmaTrac.





READ SOURCE

Leave a Reply